RT Journal Article
T1 European society of clinical microbiology and infectious diseases guidelines for coronavirus disease 2019: an update on treatment of patients with mild/moderate disease.
A1 Bartoletti, Michele
A1 Azap, Ozlem
A1 Barac, Aleksandra
A1 Bussini, Linda
A1 Ergonul, Onder
A1 Krause, Robert
A1 Martin-Quiros, Alejandro
A1 Paño-Pardo, José Ramón
A1 Power, Nicholas
A1 Sibani, Marcella
A1 Szabo, Balint Gergely
A1 Tsiodras, Sotirios
A1 Zollner-Schwetz, Ines
A1 Rodríguez-Baño, Jesús
K1 COVID-19
K1 Cilgavimab
K1 ESCMID
K1 Molnupiravir
K1 Nirmatrelvir/ritonavir
K1 Outpatients
K1 Remdesivir
K1 Sotrovimab
K1 Tixagevimab
AB Despite the large availability of vaccines, coronavirus disease 2019 (COVID-19), induced by severe acute respiratory syndrome coronavirus 2, continues to be a major threat for health-care providers and fragile people. A number of options are now available for outpatients with mild-to-moderate COVID-19 at the risk of disease progression for the prevention of deaths or hospitalization. A European Society of Clinical Microbiology and Infectious Diseases COVID-19 guidelines task force was established by the European Society of Clinical Microbiology and Infectious Diseases Executive Committee. A small group was established, half appointed by the chair and the remaining selected based on an open call. Each panel met virtually once a week. For all decisions, a simple majority vote was used. A long list of clinical questions using the population, intervention, comparison, outcome format was developed at the beginning of the process. For each population, intervention, comparison, outcome, two panel members performed a literature search, with a third panelist involved in case of inconsistent results. Voting was based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. In this update, we focus on anti-viral agents, monoclonal antibodies (mAbs) and other treatment options proposed for patients with mild or moderate COVID-19 who are at the risk of hospitalization or death. Although the use of anti-virals is recommended, especially nirmatrelvir/ritonavir and remdesivir or, alternatively, molnupirarvir, the administration of mAbs against the spike protein strictly depends on circulating variants or the ability to test timely for variants and sub-variants. At the time of writing (April-June 2022), the only active mAb was tixagevimab/cilgavimab given the predominance of the Omicron BA.2, BA.3, BA.4 and BA.5 sub-lineages in Europe. However, considering that the epidemiological scenario is extremely dynamic, constant monitoring of variants of concern is mandatory.
YR 2022
FD 2022-08-24
LK http://hdl.handle.net/10668/22136
UL http://hdl.handle.net/10668/22136
LA en
DS RISalud
RD Apr 9, 2025